Ascendis Pharma A/S (ASND)
NASDAQ:ASND
Want to see ASND full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.83Last Year’s EPS
-0.95Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and financial achievements—rapid revenue generation (EUR 247M Q1), robust YORVIPATH adoption (>1,000 new U.S. patients in the quarter; >6,300 cumulative), YUVIWEL FDA approval with early prescriptions, solid non-IFRS profitability and a healthy cash position augmented by a USD 187.5M PRV sale—supporting a growth and commercialization narrative. Offsetting items include one-time EUR 15M Q1 headwinds, elevated noncash finance expense (EUR 63M), GAAP net profit driven by a large deferred tax asset, rising SG&A, an R&D decline influenced by an inventory write-up, and the discontinuation of an internal oncology program. Overall, positives around product approvals, commercial traction, pipeline data (notably the COACH combo), and balance sheet actions outweigh the listed lowlights, though some one-time accounting and legal/operational uncertainties temper near-term clarity.Company Guidance
Strong Q1 Revenue and Commercial Scale
Total Q1 2026 revenue of EUR 247 million (including EUR 6 million collaboration revenue); YORVIPATH global revenue EUR 197 million and SKYTROFA EUR 44 million, supporting rapid revenue growth and commercial scale.
YORVIPATH Uptake and Patient Metrics
More than 1,000 new U.S. patients prescribed YORVIPATH in Q1; cumulative >6,300 patients prescribed through March 2026 by >2,700 unique health care providers, underlining sustained adoption and prescriber expansion (+~300 prescribers QoQ).
Profitability and Margins
Reported operating profit EUR 25 million (10% operating margin); non-IFRS operating profit EUR 55 million with 22% non-IFRS operating margin, with management expecting meaningful margin improvement as revenue scales.
Cash Position and Balance Sheet Actions
Ended Q1 2026 with EUR 573 million cash and cash equivalents (after EUR 60 million of share repurchases and RSU settlements); completed full redemption of outstanding convertible senior notes and transitioned to direct NASDAQ listing.
YUVIWEL FDA Approval and Early Commercial Traction
FDA approval of YUVIWEL (third FDA-approved TransCon product); commercially available in the U.S. in early April and prescribed for more than 60 children by >35 unique HCPs within weeks, with EU regulatory decision expected Q4 2026.
Realized Non-Operating Cash Benefit: PRV Sale
Announced agreement to sell Priority Review Voucher (PRV) for USD 187.5 million in cash (PRV awarded upon YUVIWEL approval), providing a sizeable one-time cash inflow.
Pipeline Depth and Positive Combination Data
More than 20 ongoing or planned clinical trials and four new preclinical entities; Phase II COACH combo (TransCon CNP + TransCon GH) showed week 52 data suggesting ~3x efficacy vs monotherapy and improvements in body proportionality and functional endpoints, potentially reducing need for invasive surgeries.
Commercial Access and Reimbursement Progress
U.S. upstream coverage expanded to ~80% of patient lives; cumulative U.S. insurance approval rate creeping toward mid-70%; over half of enrolled patients approved within ~8 weeks, indicating improving access metrics.
ASND Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ASND Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $235.90 | $246.14 | +4.34% |
Feb 11, 2026 | $221.49 | $218.10 | -1.53% |
Nov 12, 2025 | $199.22 | $206.45 | +3.63% |
Aug 07, 2025 | $190.35 | $191.49 | +0.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ascendis Pharma A/S (ASND) report earnings?
Ascendis Pharma A/S (ASND) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Ascendis Pharma A/S (ASND) earnings time?
Ascendis Pharma A/S (ASND) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ASND EPS forecast?
ASND EPS forecast for the fiscal quarter 2026 (Q2) is 1.83.